Sonnet biotherapeutics announces presentations at the 2023 cytokine-based drug development summit and provides preliminary update on the son-080 study in chemotherapy-induced peripheral neuropathy

Princeton, nj / accesswire / june 23, 2023 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that john cini, phd, chief scientific officer and co-founder, and richard kenney, md, chief medical officer, will be featured speakers at the 4th annual cytokine-based drug development summit in boston, massachusetts, june 27-29. presentation details: june 27, 1:00 - 4:00 pmjohn cini will co-lead a workshop entitled, "examining cytokine biology to develop a specific &effective drug" june 29, 2:40 - 3:10 pmrichard kenney will deliver a talk entitled, "a tale of two forms of il-12: the benefits of extending pk" cipn study (sb211) preliminary update in the sb211 study, patients are being randomized to one of three treatment groups that receive 20 Μg son-080, 60 Μg son-080, or a matching placebo in a blinded fashion, three times a week for 12 weeks.
SONN Ratings Summary
SONN Quant Ranking